The 2026 Global Medical Trend Rates Report by Aon is in, and the headline number is 9.8%.
That’s the projected global medical trend rate for 2026. It shows healthcare cost spikes (in employer-sponsored health plans) across 100+ countries.
It’s the first time since 2023 that the number has dipped back into single digits. But this isn’t stabilisation. It’s structural pressure reshaping the system.
When we look closely, here are the signals the Aon’s 2026 report gives for anyone building in healthtech.
First: Costs are rising faster than economies
Global general inflation for 2026 is projected at around 2.7%. But healthcare inflation: 9.8%. And that’s a huge gap.
This gap tells us that healthcare isn’t reacting only to macroeconomics. It’s being driven by utilisation, chronic disease, pharma innovation, and private sector demand.
It is a systemic strain.
The world is moving in different directions
The global average hides sharp regional divergence.
In the Asia-Pacific, the demand is exploding.
Projected medical trend: 11.3%
Inflation is cooling in many APAC countries, but not medical costs. And the key drivers are:
- Aging populations
- Rapid chronic disease growth
- Increased healthcare utilization
- Adoption of advanced medical technologies
India sits above 11%. Indonesia approaches 17%.
APAC isn’t just a growth market for healthtech. It’s becoming a utilisation-heavy ecosystem where preventive and remote models will become essential.
In Europe, we see a temporary cooling.
Projected trend: 8.2%
Europe sees some moderation as post-pandemic backlogs settle. But beneath the surface:
- Public systems remain capacity-constrained
- Ageing populations continue to drive demand
- Private care utilisation is rising.
The UK shows a dramatic drop from 17% to 12%. But it reflects normalisation, and not structural reform.
Latin America & the Middle East show volatility
While Latin America sits just above 10%, the Middle East & Africa remain the highest globally at over 15% gross trend.
Key cost drivers there are:
- Dependence on imported pharmaceuticals
- Currency fluctuations
- Adoption of advanced technologies
- High-cost claims
In many of these markets, inflation masks true healthcare inflation. When you strip it out, real medical cost growth is still aggressive.
These regions are highly sensitive to pharma pricing and speciality drug adoption.
The real culprits: Conditions and risk factors
The top global cost drivers are unchanged.
- Cardiovascular disease remains the top cost driver globally, hitting hardest in APAC, Europe, and LAC.
- Cancer is a top-five threat in every region.
- Hypertension is both a condition and a risk multiplier. It continues to fuel claims and serves as the gateway to more serious conditions.
- Diabetes is steadily rising.
- New for 2026, musculoskeletal issues have cracked the top five.
That last one matters. Because musculoskeletal (MSK) issues entering the global top five reflects:
- Sedentary lifestyles
- Aging workforces
- Chronic pain burdens
- Digital-era ergonomics
MSK digital platforms, AI-driven posture tracking, and remote physio are no longer niche verticals. They are the response to a macro cost driver.
Then, there are the root causes: physical inactivity, poor nutrition, and obesity. These are the silent accelerants behind nearly all of the conditions.
The emergence of GLP-1s
This year’s report puts a spotlight on GLP-1 therapies available in over 60% of surveyed countries. They are rewiring pharmacy budgets worldwide.
Three factors converge:
- Diabetes is a top cost condition
- Obesity is a top global risk factor
- Prescription drugs are now the third-largest medical plan cost component worldwide
GLP-1s hold real promise for population health, but they are also driving up costs fast. In some markets, they account for:
- Around 10% of the entire medical trend
- Up to 25% in high-adoption environments
GLP-1s are a pharmaceutical breakthrough with genuine population health potential. But simultaneously inflate short-term system costs.
For healthtech, this creates a layered opportunity:
- Digital metabolic monitoring
- GLP-1 adherence and outcomes tracking
- Companion lifestyle platforms
- Alternative obesity interventions
- Value-based reimbursement models
What Aon’s 2026 report signals for healthtech builders
The most important takeaway isn’t that healthcare costs are rising. It’s where they’re rising.
The pressure points are clear:
- Cardiometabolic disease
- Oncology
- Musculoskeletal issues
- Specialty pharmaceuticals
- Private sector demand
- Aging populations
- Utilisation growth
Every one of those pressure points aligns with active healthtech verticals.
When costs accelerate:
- Payers seek utilisation management
- Providers seek efficiency tools
- Pharma seeks outcome justification
- Employers seek prevention
- Governments seek digital scalability
Healthcare inflation is creating urgency. And urgency creates adoption.
The bigger picture
A 9.8% global medical trend rate may look like moderation. But structurally:
- Healthcare is outpacing economic growth.
- Chronic diseases remain entrenched.
- Pharmaceutical innovation is expensive.
- Utilisation is rising in ageing regions.
- Prevention is still under-leveraged.
For the healthtech ecosystem, 2026 is about building solutions in the exact places the cost curve is screaming.
Because wherever costs are rising fastest, innovation tends to follow.
